Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1

Conditions

Wilms Tumor 1Multiple Myeloma 1

Interventions

Vincristine 16Cyclophosphamide 16Filgrastim 13Etoposide 12Doxorubicin 12Radiotherapy 11Carboplatin 10X-Rays 9Dactinomycin 9Specimen Handling 8Phantoms, Imaging 8Magnetic Resonance Spectroscopy 8Granulocyte Colony-Stimulating Factor 8Temozolomide 6Melphalan 6Ifosfamide 6Topotecan 5Polymerase Chain Reaction 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Irinotecan 5Busulfan 5Biopsy 5sargramostim 4Stem Cell Transplantation 4Gene Expression Profiling 4Amplified Fragment Length Polymorphism Analysis 4Thiotepa 3Reverse Transcriptase Polymerase Chain Reaction 3Radiation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × Immunomodulating Agents × Genitourinary × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡